Immunai Strengthens Collaboration with AstraZeneca for Enhanced Research in Israel

Emerging from the forefront of technological advancement and biomedical insights, Israeli firm Immunai has taken a significant step forward in the realm of drug discovery with the announcement of a pivotal strategic agreement with the global pharmaceutical leader, AstraZeneca. This collaboration marks not just a financial milestone, with Immunai securing $18 million in initial research funding from AstraZeneca, but more importantly, it represents the inception of a deep-rooted, multi-year partnership between the two powerhouses. The gravity of this alliance is such that AstraZeneca itself has taken the initiative to make this announcement, underlining the potential it sees in Immunai’s cutting-edge AI-based tools designed to revolutionize drug discovery processes.

Immunai has not been a stranger to forming alliances within the pharmaceutical industry. Before this landmark agreement with AstraZeneca, it had already established strategic ties with 30 other pharmaceutical companies. However, those previous agreements generally involved considerably smaller financial outlays. This new, expansive deal with AstraZeneca builds upon an initial agreement formed in 2022, setting the stage for a broader collaboration that is expected to significantly advance the capabilities and applications of Immunai’s technologies.

At the heart of Immunai’s innovative approach is a comprehensive model of the human body, with a particular focus on the immune system. This model serves as a foundation for offering pharmaceutical companies an unprecedented tool to enhance drug development efficiency. Using this model, companies can navigate the complex landscape of drug development more effectively, identifying the most promising molecules, determining optimal drug combinations for trials, and establishing appropriate dosages among other key decisions. Immunai’s CEO and co-founder, Noam Solomon, likened their initial vision to being the “Google of the immune system,” a description that has since evolved. Solomon now compares their platform to being the “ChatGPT of drugs,” highlighting the system’s ability to engage with researchers in a dynamic discussion about various courses of action, albeit not through text. This comparison illuminates the platform’s capacity not only to guide researchers but also to provide explanations—both to the researchers and regulators—on why certain pathways were chosen over others.

Solomon has pointed out a fundamental issue within the realm of drug development: the inefficiency paradox. While computational biology has primarily focused on the drug discovery stage, this stage accounts for less than 5% of the total cost associated with bringing a new drug to market. The real challenges and costs arise in later stages, including drug formulation, dosing, and the execution of clinical trials. These stages carry the highest risk of failure and are the most financially demanding aspects of drug development. Addressing this, Solomon refers to “Eroom’s law” — Moore’s law spelled backwards — to highlight the declining efficiency in drug development as time progresses, despite technological advancements. Immunai’s solutions are tailored to tackle these critical pain points, promising a more efficient path through the intricate process of drug development.

Fascinatingly, every project undertaken by Immunai, including its collaborative efforts with AstraZeneca, serves to refine and enhance its AI platform. Solomon notes a trend toward increasing automation within their projects, driven by an expanding pool of data and clinical samples. This growing database not only improves the accuracy of the platform’s predictions but also reduces the resources necessary for each new project, amplifying the overall impact and efficiency of their system.

Immunai’s progress and its ambitions are underpinned by significant financial support, having raised $300 million to date. A remarkable $215 million of this was secured in a single funding round in 2021, catapulting the company’s valuation to over $1 billion. Solomon emphasizes the company’s strong financial position, with the majority of the funds still intact, thanks in part to the revenue generated from collaborations with pharmaceutical firms. Moreover, with a team of 170 employees, Immunai prides itself on maintaining an optimal size that fosters innovation without necessitating layoffs, even amidst the challenges faced by the biomed sector in recent years.

Looking to the future, Solomon envisions a shift towards financial self-sufficiency within two years, driven by ongoing ambitious goals that may warrant further funding rounds. While the long-term business model remains open to adaptation, whether it involves deeper partnership models with pharmaceutical companies or taking a more substantial ownership role in the final drug products, the immediate focus remains on excelling in their current endeavors.

Iker Huerga, AstraZeneca’s chief data scientist, lauds the collaboration, noting that “Artificial Intelligence is transforming cancer drug discovery and clinical development.” This partnership with Immunai is expected to supercharge AstraZeneca’s data-driven R&D strategy, unlocking new insights into the action mechanisms of immunotherapies and potentially accelerating the delivery of life-saving treatments to patients worldwide.

As the realms of biotechnology, artificial intelligence, and pharmaceuticals continue to intersect and evolve, partnerships like that between Immunai and AstraZeneca herald a new era of drug discovery and development. By leveraging cutting-edge AI tools and collaborative innovation, these companies are poised to tackle some of healthcare’s most daunting challenges, paving the way for breakthrough treatments that could transform millions of lives.

For more information on trending news articles like this, visit DeFi Daily News.

Published by Globes, Israel business news – en.globes.co.il – on September 26, 2024.